CJC-1295/Ipamorelin for Sleep & Recovery

Candidate profile

Adults 30+ experiencing declining sleep quality (difficulty entering deep sleep, non-restorative sleep, prolonged recovery between training sessions) that correlates with age-related GH decline. Particularly relevant for individuals whose IGF-1 levels are in the lower tertile for their age — measurable with a standard blood test.

Not appropriate for individuals with active malignancy, uncontrolled diabetes, or a history of pituitary tumors.

Approach

Pre-bedtime subcutaneous injection of CJC-1295 (no DAC) combined with Ipamorelin to amplify the natural nocturnal GH pulse. The combination targets two complementary receptors: CJC-1295 as a GHRH analog stimulates pituitary GH release, while Ipamorelin as a ghrelin mimetic amplifies the pulse amplitude without the cortisol or prolactin elevation seen with other GH secretagogues (GHRP-6, GHRP-2).

Protocol design

Peptides: CJC-1295 (no DAC) 100 mcg + Ipamorelin 100 mcg

Route: Subcutaneous (abdominal or thigh)

Timing: 30–60 minutes before sleep, on an empty stomach (food/glucose suppress GH release)

Frequency: 5 days on / 2 days off (to mitigate receptor desensitization)

Duration: 8–12 week cycle, followed by 4–6 week break

Important distinction: CJC-1295 without DAC (Drug Affinity Complex) has a half-life of ~30 minutes, producing a pulsatile GH release that mimics physiology. CJC-1295 with DAC has a half-life of days and produces sustained GH elevation — less physiological and potentially more side-effect-prone. This protocol specifies no-DAC.

Expected timeline

Week 1: Subjective sleep quality improvement is the most commonly reported first effect — deeper sleep, more vivid dreams, feeling more rested upon waking. This is partly GH-mediated (GH promotes slow-wave sleep) and partly the indirect effect of Ipamorelin on sleep architecture.

Weeks 2–4: Recovery between training sessions improves. Delayed-onset muscle soreness (DOMS) duration may decrease. Morning joint stiffness, common in 40+ athletes, often improves.

Weeks 4–8: Body composition shifts become measurable — modest fat loss (especially abdominal) and lean mass retention. These effects are subtle at physiological GH levels — don't expect GH-replacement-level changes.

Weeks 8–12: Full effect plateau. IGF-1 levels should be retested to confirm elevation from baseline (target: upper-normal range for age, not supraphysiological).

Monitoring

• IGF-1 blood test: Baseline, 4 weeks, and end of cycle. Confirms the peptides are producing the intended GH elevation.
• Fasting glucose / A1C: GH is a counter-regulatory hormone that can worsen insulin sensitivity. Monitor at baseline and 8 weeks.
• Subjective sleep tracking: Sleep quality scores, time to sleep onset, perceived recovery (1–10 scale)

Lifestyle requirements

The GH-releasing effect is blunted or eliminated by:

• Eating within 2 hours of injection — insulin suppresses GH release
• High cortisol at bedtime — stress management and evening wind-down protocols matter
• Alcohol — suppresses GH release and disrupts sleep architecture, counteracting the peptide's purpose

Maximize the protocol's effectiveness with a consistent sleep schedule, dark/cool bedroom environment, and evening meal completed at least 2–3 hours before injection.

Combination options

• DSIP (Delta Sleep-Inducing Peptide): Can be added for more direct sleep induction, though DSIP's evidence is older and less robust than the GH secretagogue data.
• Sermorelin: Can substitute for CJC-1295 as the GHRH component — cheaper but potentially less potent per mcg.

Evidence reality check

CJC-1295 and Ipamorelin reliably elevate GH in clinical settings. The translation from "elevated GH" to "improved sleep quality and recovery" is well-supported by GH physiology but has not been validated in a dedicated sleep-outcome RCT for these specific peptides. The use case is physiologically sound and widely reported by practitioners and users, but the formal clinical evidence trail is indirect.